Home › Merck Advances Development Program for Investigational Alzheimers Disease Therapy, MK-8931
 

Keywords :   


Merck Advances Development Program for Investigational Alzheimers Disease Therapy, MK-8931

2013-12-10 13:00:00| Merck.com - Product News

Dateline City: WHITEHOUSE STATION, N.J. Data Monitoring Committee recommends continuation of Phase II/III EPOCH study in mild to moderate disease patients Merck also plans to initiate dosing in Phase III study of prodromal disease patients WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an update on the development program for MK-8931, a novel investigational oral -amyloid precursor protein site-cleaving enzyme (BACE) inhibitor. Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639Justine OMalley, 908-423-2021orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: development program disease therapy

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.10Glatfelter Develops Biobased Espresso Lid Material
06.10Tropical Storm Milton Potential Storm Surge Flooding Map
06.10Tropical Storm Milton Probabilistic Storm Surge Graphics
06.10Firms urge mayor to rethink congestion charge plan
06.10Tropical Storm Milton Public Advisory Number 5
06.10Summary for Tropical Storm Milton (AT4/AL142024)
06.10Tropical Storm Milton Graphics
06.10Tropical Storm Milton Graphics
More »